Cook Children's Medical Center   Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3
Founded: Forth Worth TX United States (1918)

Organization Overview

First Clinical Trial
1998
NCT00003217
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

Adrian Lacy | Cook Children's Health Care System | Cook Children's Health Care System (maeghan.granger@cookchildrens.org) | Cook Children's Medical Center | Cook Children's Medical Center - Fort Worth | Cook Children's Physician Network | Javier Gelvez, MD

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carbohydrate Metabolism, Inborn Errors (Phase 2)

Congenital Hyperinsulinism (Phase 1)

Cystic Fibrosis (Phase 2)

Fibrosis (Phase 2)

Glioma (Phase 2)

Heart Diseases (Phase 2)

Hemophilia A (Phase 2)

Hyperinsulinism (Phase 1)

Hypoplastic Left Heart Syndrome (Phase 2)

Insulinoma (Phase 1)

Leukemia (Phase 3)

Leukemia, Lymphoid (Phase 3)

Lymphoma (Phase 1)

Lymphoma, Non-Hodgkin (Phase 1)

Neuroblastoma (Phase 1)

Precursor Cell Lymphoblastic Leukemia-Lymphoma (Phase 3)

Staphylococcal Infections (Phase 2)

Syndrome (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 16
  • # of Trial APIs: 36